文献速递神经肿瘤神经重症

恶性脑肿瘤地塞米松剂量证据的系统综述

Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know?
PubMed 文献 · J Neurooncol · 2019-07-25

多数研究使用16 mg/日(4 mg每日四次)方案;因研究异质性无法定量合并。对脑转移,较高剂量可能增加不良事件但未必改善临床状态,部分研究提示与更短生存相关;胶质瘤中无直接比较不同剂量的研究,水肿和生存结果矛盾。

要点

  • 多数研究地塞米松方案为16 mg/日(4 mg每日四次)
  • 脑转移患者高剂量可能增加不良事件且未必改善临床状态
  • 胶质瘤缺乏直接比较不同剂量的研究,证据矛盾

核心结论

  • 不同地塞米松剂量在恶性脑肿瘤患者中的安全性和有效性证据稀缺且矛盾。
  • 现有最佳证据提示低剂量在某些情况下可能不劣于高剂量。
  • 亟需更多比较研究,尤其考虑到免疫治疗在脑肿瘤中日益重要。

研究设计与样本

  • 系统检索PubMed、Embase、Web of Science、Cochrane、Academic Search Premier和PsycINFO。
  • 因研究异质性无法进行定量荟萃分析。

主要发现

  • 多数研究报告地塞米松剂量为16 mg,多为4 mg每日四次方案。
  • 脑转移患者中,较高剂量地塞米松可能增加不良事件,但未必改善临床状态。
  • 部分研究提示姑息治疗中较高地塞米松剂量与更短生存相关。
  • 胶质瘤中地塞米松可能改善症状,但无研究直接比较不同剂量。
  • 胶质瘤患者水肿减少和生存结果的研究结论相互矛盾。

关键数值与推荐

  • 多数研究采用地塞米松16 mg/日(4 mg每日四次)方案。

临床怎么用

  • 临床应基于现有有限证据个体化选择地塞米松剂量,避免盲目高剂量。
  • 对脑转移患者需权衡高剂量地塞米松的不良事件与潜在生存影响。
  • 胶质瘤患者使用地塞米松改善症状时,缺乏剂量比较证据支持特定方案。

局限性

  • 证据稀缺且研究间异质性大,无法定量合并。
  • 缺乏直接比较不同地塞米松剂量的研究,尤其胶质瘤。
  • 未涉及免疫治疗背景下地塞米松剂量影响的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The present study aims to conduct a systematic review of literature reporting on the dose and dosing schedule of dexamethasone (DXM) in relation to clinical outcomes in malignant brain tumor patients, with particular attention to evidence-based practice. METHODS: A systematic search was performed in PubMed, Embase, Web of Science, Cochrane, Academic Search Premier, and PsycINFO to identify studies that reported edema volume reduction, symptomatic relief, adverse events and survival in relation to dexamethasone dose in glioma or brain metastasis (BM) patients. RESULTS: After screening 1812 studies, fifteen articles were included for qualitative review. Most studies reported a dose of 16 mg, mostly in a schedule of 4 mg four times a day. Due to heterogeneity of studies, it was not possible to perform quantitative meta-analysis. For BMs, best available evidence suggests that higher doses of DXM may give more adverse events, but may not necessarily result in better clinical condition. Some studies suggest that higher DXM doses are associated with shorter survival in the palliative setting. For glioma, DXM may lead to symptomatic improvement, yet no studies directly compare different doses. Results regarding edema reduction and survival in glioma patients are conflicting. CONCLUSIONS: Evidence on the safety and efficacy of different DXM doses in malignant brain tumor patients is scarce and conflicting. Best available evidence suggests that low DXM doses may be noninferior to higher doses in certain circumstances, but more comparative research in this area is direly needed, especially in light of the increasing importance of immunotherapy for brain tumors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Jessurun CAC, Hulsbergen AFC, Cho LD, et al. Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know? J Neurooncol. 2019. PMID: 31346902. doi:10.1007/s11060-019-03238-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。